TORONTO and CHICAGO, May 21, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging data-driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the expansion of its…


Previous articleCybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
Next articlePTSF60 – Representation and Access, with Elan Hagens and Rebecca Martinez of Fruiting Bodies Collective